EG 001
Alternative Names: EG-001Latest Information Update: 04 Aug 2024
At a glance
- Originator Evergreen Therapeutics
- Class Anti-inflammatories; Antifibrotics
- Mechanism of Action Epithelial sodium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Idiopathic pulmonary fibrosis
Most Recent Events
- 31 Jul 2024 Phase I clinical development in Idiopathic pulmonary fibrosis is ongoing USA (PO, Capsule).(Shenzhen Eglin Pharmaceutical pipeline, July 2024)
- 19 Apr 2022 EG 001 is available for licensing as of 19 Apr 2022.
- 11 Apr 2022 Shenzhen Eglin Pharmaceutical pipeline, April 2022- Updated ODD status for the candidate. Profile viewed